Medicamen Biotech's Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Medicamen Biotech Ltd reported a 0.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 4.8%.
- Its expenses for the quarter were up by 1.0% QoQ and 9.5% YoY.
- The net profit decreased 22.6% QoQ and decreased 43.8% YoY.
- The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.21 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 47.44 | 47.54 | 45.28 | -0.2% | 4.8% |
Total Expenses | 45.33 | 44.86 | 41.41 | 1.0% | 9.5% |
Profit Before Tax | 2.11 | 2.68 | 3.88 | -21.3% | -45.6% |
Tax | 0.48 | 0.57 | 0.96 | -15.8% | -50.0% |
Profit After Tax | 1.64 | 2.12 | 2.92 | -22.6% | -43.8% |
Earnings Per Share | 1.21 | 1.56 | 2.30 | -22.4% | -47.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Medicamen Biotech Ltd is a pharmaceutical company engaged in the manufacturing and distribution of a wide range of pharmaceutical products. The company operates within the healthcare industry, focusing on the production of both generic and branded pharmaceutical formulations. While specific recent developments are not detailed in the provided information, companies in this sector often engage in research and development to expand their product lines or improve existing formulations. Medicamen Biotech Ltd may offer products across various therapeutic segments, catering to diverse healthcare needs.
Revenue
For the quarter ending Q3FY26, Medicamen Biotech Ltd reported a total income of ₹47.44 crores. This represents a slight decrease of 0.2% compared to the previous quarter (Q2FY26), where total income was ₹47.54 crores. However, on a year-over-year basis, the company experienced a 4.8% increase in total income compared to Q3FY25, when it was ₹45.28 crores. This indicates a growth in revenue over the year, despite the quarterly dip.
Profitability
During Q3FY26, Medicamen Biotech Ltd recorded a Profit Before Tax (PBT) of ₹2.11 crores, reflecting a decrease of 21.3% from ₹2.68 crores in Q2FY26. The year-over-year comparison shows a more pronounced decline of 45.6% from Q3FY25, when PBT was ₹3.88 crores. The tax for Q3FY26 amounted to ₹0.48 crores, a reduction of 15.8% from the previous quarter and 50.0% from the same quarter last year. As a result, the Profit After Tax (PAT) for Q3FY26 stood at ₹1.64 crores, down 22.6% from Q2FY26's ₹2.12 crores and 43.8% lower than Q3FY25's ₹2.92 crores. The Earnings Per Share (EPS) for Q3FY26 was ₹1.21, compared to ₹1.56 in Q2FY26 and ₹2.30 in Q3FY25, indicating a reduction in shareholder earnings both quarterly and annually.
Operating Metrics
Total Expenses for Medicamen Biotech Ltd in Q3FY26 were ₹45.33 crores, marking a 1.0% increase from ₹44.86 crores in Q2FY26. On a year-over-year basis, expenses rose by 9.5% from ₹41.41 crores in Q3FY25. This increase in expenses has impacted the profitability metrics as discussed, with reductions in PBT, PAT, and EPS. The financial ratios such as P/E ratio, debt-to-equity ratio, and current ratio are not directly available from the data provided. However, the trends observed in the income and expenses provide insight into the company's operating environment during the quarter.